Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls

Journal of Neurology

Volumn 260, Issue 5, 2013, Pages 1420-1422

  Cardo, Lucía F ^a   Coto, Eliecer ^a,b   De Mena, Lorena ^a   Ribacoba, Renée ^c   Moris, Germán ^c   Menéndez, Manuel ^c   Alvarez, Victoria ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Hospitales Universitario Central Asturias and á Lvarez Buylla Mieres ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN331 MICRORNA, HUMAN;

AGED; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; NONPARAMETRIC TEST; PARKINSON DISEASE; LETTER;

AGED; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PARKINSON DISEASE; STATISTICS, NONPARAMETRIC;

EID: 84891391234     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6900-8     Document Type: Letter

References (15)

1. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici, K (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318:121-134.
2. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: A mutation update. Hum Mutat 31:763-780.
3. Eacker SM, Dawson TM, Dawson VL (2009) Understanding microRNAs in neurodegeneration. Nat Rev Neurosci 10:837-841.
4. Kim J, Inoue K, Ishii J, Vanti WB, Voronov SV, Murchison E, Hannon G, Abeliovich A (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317:1220-1224.
5. Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, Scott WK, Martin ER, Vance JM (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82:283-289.
6. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM (2009) Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 106:13052-13057.
7. Gehrke S, Imai Y, Sokol N, Lu B (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466:637-641.
8. Minones-Moyano E, Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, Espinosa-Parrilla Y, Ferrer I, Estivill X, Marti E (2011) MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet 20:3067-3078.
9. Reid G, Kirschner MB, van Zandwijk, N (2011) Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 80:193-208.
10. Olivieri F, Spazzafumo L, Santini G, Lazzarini R, Albertini MC, Rippo MR, Galeazzi R, Abbatecola AM, Marcheselli F, Monti D, Ostan R, Cevenini E, Antonicelli R, Franceschi C, Procopio AD (2012) Age-related differences in the expression of circulating microRNAs: miR-21 as a new circulating marker of inflammaging. Mech Ageing Dev 133:675-685.
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
12. Geekiyanage H, Jicha GA, Nelson PT, Chan C (2012) Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol 235:491-496.
13. Li X, Khanna A, Li N, Wang E (2011) Circulatory miR34a as an RNA based, noninvasive biomarker for brain aging. Aging (Albany NY) 3:985-1002.
14. Martins M, Rosa A, Guedes LC, Fonseca BV, Gotovac K, Violante S, Mestre T, Coelho M, Rosa MM, Martin ER, Vance JM, Outeiro TF, Wang L, Borovecki F, Ferreira JJ, Oliveira SA (2011) Convergence of miRNA expression profiling, alpha-synuclein interaction and GWAS in Parkinson's disease. PLoS ONE 6:e25443.
15. Margis R, Rieder CR (2011) Identification of blood microRNAs associated to Parkinson's disease. J Biotechnol 152:96-101.